Article
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.
European journal of cancer (Oxford, England : 1990) - 1 Sept 2023
Livingstone E, Gogas H, Kandolf-Sekulovic L, Meier F, Eigentler T K, Ziemer M, Terheyden P A M, Gesierich A H, Herbst R A, Kähler K C, Ziogas D C, Mijuskovic Z, Garzarolli M, Garbe C, Roesch A, Ugurel S, Gutzmer R, Grob J J, Kiecker F, Utikal J, Windemuth-Kieselbach C, Eckhardt S, Zimmer L, Schadendorf D
Abstract excerpt
AIM: ImmunoCobiVem investigated whether a planned switch to atezolizumab after achieving tumour control during run-in with vemurafenib + cobimetinib improves progression-free survival (PFS) and overall survival (OS) compared to continuous targeted therapy (TT) in patients with previously untreated advanced BRAFV600-mutated melanoma. METHODS: In this multicenter phase 2 study, patients received vemurafenib plus...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.